News
NWPHF
2.100
NaN%
--
Analysts Conflicted on These Healthcare Names: Newron Pharmaceuticals SpA (OtherNWPHF) and CSL (OtherCMXHF)
TipRanks · 10/22 13:10
Newron Completes Enrollment in Pivotal Phase 3 Schizophrenia Study
TipRanks · 10/22 05:32
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)
TipRanks · 10/12 10:40
Newron Pharma price target lowered to CHF 30 from CHF 44 at H.C. Wainwright
TipRanks · 10/12 10:25
Newron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal
TipRanks · 10/08 05:34
Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review
TipRanks · 10/08 05:32
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF) and Newron Pharmaceuticals SpA (OtherNWPHF)
TipRanks · 10/04 22:40
Newron Pharma price target lowered to CHF 19 from CHF 35 at Roth Capital
TipRanks · 10/04 22:30
Newron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial
TipRanks · 09/25 16:03
Newron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts
TipRanks · 09/22 05:33
Newron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss
TipRanks · 09/22 05:32
Newron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program
TipRanks · 09/08 05:33
Newron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription
TipRanks · 09/08 05:32
Analysts Offer Insights on Healthcare Companies: Newron Pharmaceuticals SpA (OtherNWPHF) and Summit Therapeutics (SMMT)
TipRanks · 09/03 10:20
Newron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia
TipRanks · 09/02 05:33
Newron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide
TipRanks · 09/02 05:33
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Newron Pharmaceuticals SpA (OtherNWPHF) and Boston Scientific (BSX)
TipRanks · 07/08 10:30
Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide
TipRanks · 07/02 16:03
H.C. Wainwright Sticks to Its Buy Rating for Newron Pharmaceuticals SpA (NWPHF)
TipRanks · 06/25 12:36
Analysts’ Top NA Picks: Newron Pharmaceuticals SpA (NWPHF), Veradermics, Incorporated (MANE)
TipRanks · 06/22 10:44
More
Webull provides a variety of real-time NWPHF stock news. You can receive the latest news about Newron Phar through multiple platforms. This information may help you make smarter investment decisions.
About NWPHF
Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.